Onconano Medicine

OncoNano Medicine, Inc., a clinical-stage biotechnology firm founded in 2014, operates from Southlake, Texas. The company spun out of the University of Texas Southwestern Medical Center, originating from a collaboration between Dr. Jinming Gao, a professor with expertise in biomedical engineering and pharmacology, and Dr. Baran D. Sumer, a cancer surgeon. Dr. Gao's work focuses on developing nanotechnology platforms for cancer diagnosis and treatment, while Dr. Sumer specializes in head and neck cancer surgery and reconstruction. Their joint efforts led to the creation of the core technology that OncoNano is built upon.

The company's business is centered on exploiting the acidic tumor microenvironment (a universal biomarker of cancer) for the diagnosis and treatment of solid tumors. OncoNano's proprietary ON-BOARD™ platform utilizes ultra pH-sensitive polymeric micelles that are designed to deliver anti-cancer payloads with high specificity to the tumor microenvironment. This approach aims to improve the efficacy of treatments while mitigating the side effects associated with conventional therapies. Revenue generation is anticipated from the commercialization of its product pipeline, supported by significant funding from sources like Advantech Capital and the Cancer Prevention and Research Institute of Texas (CPRIT).

OncoNano's lead product candidate, pegsitacianine (formerly ONM-100), is an injectable, fluorescent imaging agent. Administered intravenously, it selectively accumulates in tumors and fluoresces in the acidic environment, allowing surgeons to visualize cancerous tissue in real-time during surgery with existing infrared cameras. This enhanced visualization is intended to enable more complete tumor removal and the preservation of healthy tissue. Pegsitacianine has received Fast Track designation from the FDA and has been evaluated in Phase 2 and 3 clinical trials for various solid tumors. Beyond imaging, the company is developing a pipeline of therapeutic candidates. ONM-501 is a dual-activating STING (STimulator of INterferon Genes) agonist designed for immuno-oncology applications and is currently in Phase 1 clinical trials. Another program, ONM-412, involves encapsulating the pro-inflammatory cytokine interleukin-12 (IL-12) to improve its tolerability and anti-tumor efficacy.

Keywords: oncology, nanotechnology, pH-sensitive micelles, cancer imaging, surgical guidance, drug delivery, tumor microenvironment, immunotherapy, STING agonist, clinical-stage biotechnology, pegsitacianine, ONM-501, intraoperative imaging, solid tumors, cancer therapeutics, targeted therapy, biopharmaceutical, clinical trials, immuno-oncology, cancer diagnostics, real-time surgical imaging, nanomedicine, precision oncology, fluorescent probe, tumor visualization